Metabolic Research Peptides: UK Evidence Review

Research Use Only. Peptides Lab UK supplies research-grade materials for in-vitro laboratory research only. Nothing on this page is medical advice or an instruction for human or animal use, and no product sold on this website is a medicine.

Scope

This page gives a neutral overview of peptides and related compounds that appear in published metabolic research, including studies of energy expenditure, adipose tissue biology and body-weight endpoints in defined models or trial populations. It does not rank products, make efficacy claims or give any dosing or human-use information.

Incretin-pathway peptides

GLP-1 and dual GIP/GLP-1 receptor agonists have the largest clinical-trial evidence base in this area. Large randomised trials of authorised medicines (for example STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide) reported body-weight endpoints in defined populations under medical supervision; these are prescription-only medicines in the UK, and the results do not apply to research-grade material.^[1,2] See our GLP-1 class research review.

MOTS-c

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene, one of a class of mitochondrial-derived peptides. It is not an authorised medicine in the UK.^[3]

Tesamorelin

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH), stabilised by an N-terminal trans-3-hexenoyl group. It has been authorised in some countries for a specific indication (excess abdominal fat in HIV-associated lipodystrophy); it is not an authorised medicine in the UK.^[4]

AOD-9604

AOD-9604 is a modified synthetic fragment corresponding to the C-terminal region (residues 177–191) of human growth hormone, with an additional N-terminal tyrosine. It was developed as a research compound to study lipolytic activity attributed to this region of growth hormone, and it is not an authorised medicine in the UK.^[5]

5-Amino-1MQ

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule, membrane-permeable inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and is linked to cellular NAD⁺ and methyl-donor metabolism. It is a research compound, not a peptide medicine, and has no marketing authorisation.^[6]

SLU-PP-332

SLU-PP-332 is a synthetic small-molecule agonist of the oestrogen-related receptors (ERRα, β and γ). It is not a peptide and has no marketing authorisation; it is a preclinical research tool.^[7]

Limitations of the evidence

Apart from authorised incretin medicines, most compounds above are supported mainly by animal or cell studies. Outcomes in rodents frequently fail to translate to humans, and no conclusions about human use should be drawn.

UK regulatory status

In the UK, medicines are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Research-grade compounds sold by Peptides Lab UK are supplied strictly for laboratory research; they are not medicinal products, are not manufactured to medicinal GMP standards and must not be used in humans or animals.

Related research pages

• Tirzepatide UK: Complete Research Guide (2026)
• Retatrutide UK: Complete Research Guide (2026)
• AOD-9604 UK: Complete Research Guide (2026)
• Tesamorelin UK: Complete Research Guide (2026)
• MOTS-C UK: Complete Research Guide (2026)

References

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021; 384(11):989-1002. doi:10.1056/NEJMoa2032183 PMID: 33567185.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022; 387(3):205-216. doi:10.1056/NEJMoa2206038 PMID: 35658024.
3. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015; 21(3):443-54. doi:10.1016/j.cmet.2015.02.009 PMID: 25738459.
4. Falutz J et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010; 53(3):311-22. doi:10.1097/QAI.0b013e3181cbdaff PMID: 20101189.
5. Heffernan MA et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001; 25(10):1442-9. doi:10.1038/sj.ijo.0801740 PMID: 11673763.
6. Neelakantan H et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018; 147:141-152. doi:10.1016/j.bcp.2017.11.007 PMID: 29155147.
7. Billon C et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024; 388(2):232-240. doi:10.1124/jpet.123.001733 PMID: 37739806.

Disclaimer: All products sold by Peptides Lab UK are for laboratory research use only. Not for human or veterinary use, not for consumption, and not intended to diagnose, treat, cure or prevent any disease. This page is an educational literature summary and is not medical advice.